RAAB MICHAEL sold $236K of ARDX

RAAB MICHAEL (President & CEO) sold 41,666 shares of ARDELYX, INC. (ARDX) at $5.67 ($0.24M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · RAAB MICHAEL
Published Jun 17, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
medium confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The only new fact is the CEO’s open-market sale details and post-transaction holdings; the text provides no company performance or forward-looking information.

02

Market read

This is a routine insider-sale filing; it may slightly influence sentiment but lacks a fundamental catalyst.

03

What to watch

Traders may over-weight insider sales; without concurrent guidance, trial, or financing news, the disclosure is unlikely to change valuation assumptions.

Relevance 3/10Novelty 4/10Timing: filed 2026-06-17 (after the 2026-06-15 sale)

Background

The article is an SEC Form 4 insider transaction for ARDELYX, Inc. (ARDX), filed via SEC EDGAR.

Company-level read

Ticker impact

$ARDXNeutralMedium confidence
Context

SEC Form 4 shows ARDX CEO Michael Raab sold 41,666 shares on 2026-06-15 at $5.6724, totaling $236,346.22.

Expected impact

Likely limited near-term impact; any effect would be short-lived unless followed by additional disclosures or company-specific news.

Evidence & confidence

The filing is a routine open-market sale under a 10b5-1 plan, with no accompanying operational or financial update in the text.

Market effects

No sector read-across; this is a single-company insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • ARDX

    Ardelyx, Inc.; subject of the Form 4 insider sale disclosure.

  • Michael Raab

    President & CEO who sold 41,666 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMed

Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

$ARDXLow

Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.